AE

:   adverse event

AIS

:   American Spinal Injury Association Impairment Scale

CI

:   confidence interval

ECOG

:   Eastern Cooperative Oncology Group

HRQOL

:   health-related quality of life

LSG

:   long-survival group

MESCC

:   metastatic epidural spinal cord compression

NRS

:   numeric rating scale

SINS

:   Spinal Instability Neoplastic Score

SF-36

:   36-Item Short Form Health Survey

SOSGOQ

:   Spine Oncology Study Group Outcomes Questionnaire

SSG

:   short-survival group

Surgery for symptomatic metastatic epidural spinal cord compression (MESCC) has become a mainstay of treatment for its evidence-based, cost-effective improvement in neurological outcome and health-related quality of life (HRQOL).^[@bib1]^ Recent advances in medical oncology, especially with targeted molecular treatment, have resulted in patients with metastatic spine disease and a seemingly dismal prognosis living longer and, therefore, challenging traditional surgical decision-making aids.^[@bib4]^ This coupled with breakthroughs in radiation and surgical technology, such as separation surgery, has left the oncologist and surgeon alike with more treatment options to maintain or improve HRQOL, but with little guidance to apply them.^[@bib5]^

For many years, the essential prerequisite to any surgical indication for patients with metastatic disease to the spine was to have an expected survival of at least 3 mo.^[@bib1],[@bib8],[@bib9]^ This surgical requirement comes from the premise that patients with short life expectancy should not be subjected to invasive surgical treatment as the likelihood of HRQOL improvement was low, adverse event (AE) profile high, and the economic balance unfavorable. These assumptions, however, are not evidenced-based, and appear to arise from inclusion criteria of landmark studies.^[@bib1]^ Furthermore, oncologists and surgeons are often inaccurate when it comes to predicting life expectancy of a cancer patient.^[@bib10]^ Questions therefore arise around the arbitrary 3-mo survival surgical indication. How can we only consider patients with more than 3 mo of life expectancy when we cannot accurately predict who will live more than 3 mo? And with a wealth of new surgical and radiation technologies available, why would someone with incapacitating mechanical pain and/or progressive neurological deficit be denied treatment because their life expectancy is believed to be less than 3 mo?

The primary objective of this paper is to investigate HRQOL in surgically treated metastatic spine disease patients with short survival; more precisely to compare the pattern of improvement in patients with short (less than 3 mo) and long (more than 3 mo) survival based on observed survival time. The secondary objective is to compare patient satisfaction with treatment between the short- (SSG) and long-survival groups (LSG). The broader goal is to contribute to the process of redefining the inclusion criteria for surgical consideration of these patients, ultimately by including variables that are measurable at the time of presentation and not expected based on inaccurate prognostic tools.^[@bib4]^

METHODS {#sec2}
=======

Patient Selection {#sec2-1}
-----------------

An international, multicenter, prospective observational cohort study was initiated in August 2013 at 10 experienced oncologic spine centers across North America and Europe. The inclusion criteria for this study included diagnosis of metastatic spine disease from any primary tumor, age between 18 and 75 yr, and treatment with surgery and or radiotherapy. The type of surgery was left to the discretion of the treating surgeon and included surgery for stability, neurology, and separation surgery. Patients were excluded if they had a central nervous system tumor or a primary spinal bone tumor. For this analysis, consecutive patients treated with surgery were retrospectively identified from this cohort, and patients treated with radiation therapy alone were excluded. The protocol was approved the ethics board of each participating center. All patients provided written informed consent for study participation. The [ClinicalTrials.gov](http://www.ClinicalTrials.gov) identifier for this study is NCT01825161.

Outcome Evaluation {#sec2-2}
------------------

Demographic, medical history, diagnostic, treatment, performance status, patient satisfaction, AE, and HRQOL data were collected prospectively. Performance status was assessed using the Eastern Cooperative Oncology Group (ECOG).^[@bib11]^ HRQOL and pain scores were evaluated at baseline and at 6, 12, 24, 52, and 104 wk after treatment or until death using the SOSGOQ (version 2.0),^[@bib12]^ the Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36, version 2.0; Medical Outcomes Trust, Boston, Massachusetts), the EQ-5D-3 L (© EuroQol Group EQ-5D), and the numeric rating scale (NRS) pain score. Patient\'s satisfaction was based on item 21 of the SOSGOQ. "Very satisfied" and "somewhat satisfied" were classified as "satisfaction," "neither satisfied nor dissatisfied" was classified as "neutral," and "somewhat dissatisfied" and "very dissatisfied" were classified as "dissatisfaction." AEs were grouped into intraoperative AE and postoperative AE. All data were stored in a secure Web-based application (Research Electronic Data Capture \[REDCap\]; Vanderbilt University, Nashville, Tennessee).

Statistical Analysis {#sec2-3}
--------------------

Two groups were compared: those with an observed survival of less than 3 mo (SSG) and those with a survival of more than 3 mo (LSG). Survival was assessed by the proportion of patients being confirmed alive or dead at day 105 post-treatment. The primary endpoint was to look at the HRQOL at 6 wk after treatment in each group using a disease-specific HRQOL tool (SOSGOQ). The secondary endpoint was to assess patient\'s satisfaction at 6 wk in both groups. Patients who were lost to follow-up before the 3-mo visit, not related to death, were excluded from the complete analysis. Only patients confirmed dead within 3 mo after surgery were included in the less than 3-mo survival group. All continuous variables were summarized using the following descriptive statistics: n (number of valid observations), mean, standard deviation, median, maximum, and minimum. The frequency and percentages of observed levels were reported for all categorical measures. Groups were compared using the *t*-test or Wilcoxon rank-sum test and chi-square test or Fisher\'s exact test, depending on the dependent variable. Ordinal data were compared by using Cochran-Armitage trend test. For repeated measurement analysis, we used an unadjusted mixed effect models with unstructured covariance to optimize the data, which will be considered for the model. To control for baseline differences, we used an adjusted mixed effect model adjusted only for baseline performance status (ECOG) because of the low number of patients in SSG.

RESULTS {#sec3}
=======

A total of 277 patients met the inclusion criteria. Twenty-four patients were lost to follow-up before the 3-mo visit and were thus not included in the analysis (Figure [1](#fig1){ref-type="fig"}). Forty patients were confirmed dead within the first 3 mo (SSG), and 213 patients survived more than 3 mo (LSG). Baseline characteristics of the population are shown in Table [1](#tbl1){ref-type="table"}. Median age was 61 yr old for the SSG and 59 for the LSG (*P* = .957), and male gender was more common in the SSG (*P* \< .001). Mean Spinal Instability Neoplastic Score (SINS) was similar in both groups (11.2 vs 10.3; *P* = .101). Baseline ECOG score was worse in the SSG (*P* = .006). Moreover, patients with short survival more frequently had lung cancer (*P* \< .001), a higher grade of epidural disease (*P* = .001), and worse American Spinal Injury Association Impairment Scale (AIS) scores (*P* \< .001) compared to the LSG. In the SSG, 27.5% received radiation therapy at any point during the study, compared to 55.9% in the LSG. Posterolateral vertebrectomy was performed less often in the SSG (39.4% vs 53.8% in the LSG), although a statistically significant difference was not detected (*P* = .193). There was no difference between both groups with regard to utilization of percutaneous fixation (*P* = 1.000), and no patient was treated with laser interstitial thermal therapy. Baseline patient-reported outcomes are shown in Table [2](#tbl2){ref-type="table"}. Baseline pain (NRS) and HRQOL as measured by the EQ5D and SOSGOQ2.0 were all significantly worse in the SSG. Kaplan-Meier survival curve stratified by ECOG for the whole analysis population is shown in Figure [2](#fig2){ref-type="fig"}.

![Patient flow chart.](nyz472fig1){#fig1}

![Kaplan-Meier plot for 1-yr mortality and patients at risk by ECOG status.](nyz472fig2){#fig2}

###### 

Baseline Patient Characteristics

  Characteristic                                                                                                                       Short-survival group N = 40   Long-survival group N = 213   Total N = 253   *P* value
  ------------------------------------------------------------------------------------------------------------------------------------ ----------------------------- ----------------------------- --------------- -----------
  Age at surgery/radiotherapy (years)                                                                                                                                                                              .957^b^
   Mean (SD)                                                                                                                           57.6 (12.1)                   57.5 (11.1)                   57.5 (11.2)     
   Gender, n (%)                                                                                                                       40                            213                           253             \<.001^c^
   Female                                                                                                                              9 (22.5)                      119 (55.9)                    128 (50.6)      
   Male                                                                                                                                31 (77.5)                     94 (44.1)                     125 (49.4)      
  ECOG classification, n (%)                                                                                                           40                            211                           251             .038^d^
   0-Fully active                                                                                                                      0 (0.0)                       24 (11.4)                     24 (9.6)        
   1-Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature                14 (35.0)                     89 (42.2)                     103 (41.0)      
   2-Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours   12 (30.0)                     55 (26.1)                     67 (26.7)       
   3-Capable of only limited self-care                                                                                                 10 (25.0)                     33 (15.6)                     43 (17.1)       
   4-Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair                                              4 (10.0)                      10 (4.7)                      14 (5.6)        
   5-Dead                                                                                                                              0 (0.0)                       0 (0.0)                       0 (0.0)         
  Site of the primary cancer, n (%)                                                                                                    40                            213                           253             \<.001^c^
   Breast                                                                                                                              0 (0.0)                       46 (21.6)                     46 (18.2)       
   Lungs                                                                                                                               16 (40.0)                     34 (16.0)                     50 (19.8)       
   Prostate                                                                                                                            1 (2.5)                       14 (6.6)                      15 (5.9)        
   Kidney                                                                                                                              3 (7.5)                       37 (17.4)                     40 (15.8)       
   Other                                                                                                                               20 (50.0)                     82 (38.5)                     102 (40.3)      
  The original primary cancer site remains controlled, n (%)                                                                           37                            211                           248             .560^c^
   No                                                                                                                                  15 (40.5)                     75 (35.5)                     90 (36.3)       
   Yes                                                                                                                                 22 (59.5)                     136 (64.5)                    158 (63.7)      
  Time since primary tumor diagnosis (months)                                                                                                                                                                      .161^e^
   Mean (SD)                                                                                                                           28.5 (41.9)                   41.0 (50.0)                   39.0 (48.9)     
  Other site(s) of metastases, n (%)^a^                                                                                                40                            213                           253             
   None                                                                                                                                9 (22.5)                      84 (39.4)                     93 (36.8)       
   Brain                                                                                                                               6 (15.0)                      10 (4.7)                      16 (6.3)        
   Visceral                                                                                                                            20 (50.0)                     70 (32.9)                     90 (35.6)       
   Axial skeletal metastases (spine/pelvis)                                                                                            15 (37.5)                     69 (32.4)                     84 (33.2)       
   Appendicular skeletal metastases                                                                                                    5 (12.5)                      30 (14.1)                     35 (13.8)       
   Other                                                                                                                               6 (15.0)                      30 (14.1)                     36 (14.2)       
  Pain, n (%)^a^                                                                                                                       40                            213                           253             
   None                                                                                                                                1 (2.5)                       7 (3.3)                       8 (3.2)         
   Axial pain                                                                                                                          34 (85.0)                     165 (77.5)                    199 (78.7)      
   Radicular pain                                                                                                                      17 (42.5)                     104 (48.8)                    121 (47.8)      
  Type of axial pain, n (%)^a^                                                                                                         34                            165                           199             
   Mechanical                                                                                                                          23 (67.6)                     131 (79.4)                    154 (77.4)      
   Biological                                                                                                                          20 (58.8)                     62 (37.6)                     82 (41.2)       
  Epidural compression for most severe compression (re-grouped), n (%)                                                                 40                            205                           245             .001^c^
   Bilsky 0-1c                                                                                                                         11 (27.5)                     113 (55.1)                    124 (50.6)      
   Bilsky 2-3                                                                                                                          29 (72.5)                     92 (44.9)                     121 (49.4)      
  AIS at baseline, n (%)                                                                                                               40                            213                           253             \<.001^d^
   A                                                                                                                                   1 (2.5)                       0 (0.0)                       1 (0.4)         
   B                                                                                                                                   3 (7.5)                       2 (0.9)                       5 (2.0)         
   C                                                                                                                                   6 (15.0)                      8 (3.8)                       14 (5.5)        
   D                                                                                                                                   12 (30.0)                     60 (28.2)                     72 (28.5)       
   E                                                                                                                                   18 (45.0)                     143 (67.1)                    161 (63.6)      
  Total SINS score                                                                                                                                                                                                 .101^b^
   n                                                                                                                                   40                            212                           252             
   Mean (SD)                                                                                                                           11.2 (3.0)                    10.3 (3.2)                    10.4 (3.2)      

^a^Multiple answer options possible.

^b^ *t*-test.

^c^Chi-square test.

^d^Fisher\'s exact test.

^e^Wilcoxon rank-sum test.

###### 

Baseline Patient-Reported Outcomes (PRO)

  Baseline PRO                         Short survival N = 40   Long survival N = 213   Total N = 253   *P* value
  ------------------------------------ ----------------------- ----------------------- --------------- -----------
  Pain NRS index                                                                                       .044^a^
   n                                   32                      204                     236             
   Mean (SD)                           7.3 (2.5)               6.4 (2.6)               6.5 (2.6)       
  EQ-5D (3 L) Score                                                                                    .001^a^
   n                                   30                      199                     229             
   Mean (SD)                           0.31 (0.24)             0.49 (0.28)             0.47 (0.28)     
  SF-36v2 physical component summary                                                                   .069^b^
   n                                   32                      201                     233             
   Mean (SD)                           26.3 (8.6)              29.5 (9.2)              29.1 (9.2)      
  SF-36v2 mental component summary                                                                     .095^b^
   n                                   32                      201                     233             
   Mean (SD)                           39.7 (12.8)             43.6 (12.0)             43.0 (12.2)     
  SOSGOQ overall score (version 2)                                                                     .052^a^
   n                                   30                      199                     229             
   Mean (SD)                           45.0 (13.9)             51.7 (18.1)             50.8 (17.7)     

^a^Wilcoxon rank sum test.

^b^ *t*-test.

An adjusted mixed effect model was performed to adjust for baseline performance status (Table [3](#tbl3){ref-type="table"}). In this model, the SSG had a statistically nonsignificant pain improvement of 1.4 points (*P* = .415), compared to 2.7 in the LSG (*P* \< .001) at 6 wk. Intragroup improvement in HRQOL from baseline to 6 wk was not significant for any outcome tools in the SSG. In the LSG, significant improvement in HRQOL at 6 wk post-treatment was found when using EQ-5D (*P* \< .001) and SOSGOQ2.0 (*P* \< .001), but not SF-36v2 physical component score (PCS) or mental component score (MCS) (*P* = .345 and *P* = .239). Intergroup comparison revealed better pain scores at 6 wk in the LSG (5.7 vs 3.6; *P* = .010). With regard to the primary outcome, there was no statistical difference in HRQOL at 6 wk between both groups as measured by the SOSGOQ2.0 (48.1 vs 61.4; *P* = .101) and also by EQ-5D (*P* = .189), SF-36 PCS (*P* = .866), and SF-36 MCS (*P* = .453). EQ-5D improved nearly equally in both groups, 0.16 in the SSG compared to 0.15 in the LSG. In surviving patients, improvement in quality of life was sustained until last available follow-up.

###### 

Adjusted Mixed-Effect Models Derived Estimates of the Differences in Mean Scores of Efficacy Endpoints (SOSGOQ, SF-36v2, EQ-5D, and Pain NRS) by Time Measurement and Analysis Group Adjusted for Baseline ECOG

                    Short survival   Long survival       Short survival/long survival                                                                     
  ----------------- ---------------- ------------------- ------------------------------ ------- ----- ------------------- ---------------------- -------- ------
  Pain NRS                                                                                                                                                
   Baseline         32               7.1 (6.2; 8.0)                                             202   6.2 (5.8; 6.6)                                      .606
   6 wk             15               5.7 (4.6; 6.9)      --1.4 (--3.4; 0.6)             .415    163   3.6 (3.2; 3.9)      --2.7 (--3.3; --2.0)   \<.001   .010
   12 wk            3                6.1 (3.9; 8.3)      --1.0 (--4.6; 2.6)             .990    155   3.2 (2.8; 3.6)      --3.0 (--3.8; --2.3)   \<.001   .164
   26 wk                                                                                        127   3.3 (2.9; 3.7)      --3.0 (--3.7; --2.2)   \<.001   
  EQ-5D (3 L)                                                                                                                                             
   Baseline         30               0.32 (0.23; 0.41)                                          197   0.45 (0.42; 0.49)                                   .089
   6 wk             15               0.48 (0.38; 0.57)   0.16 (--0.03; 0.35)            .146    160   0.61 (0.57; 0.64)   0.15 (0.09; 0.22)      \<.001   .189
   12 wk            3                0.37 (0.20; 0.54)   0.06 (--0.23; 0.34)            .999    152   0.68 (0.65; 0.71)   0.23 (0.17; 0.29)      \<.001   .009
   26 wk                                                                                        126   0.66 (0.63; 0.70)   0.21 (0.14; 0.28)      \<.001   
  SF-36v2 PCS                                                                                                                                             
   Baseline         32               26.8 (23.7; 29.8)                                          199   28.7 (27.3; 30.1)                                   .935
   6 wk             12               27.0 (22.5; 31.6)   0.3 (--7.4; 8.0)               1.000   156   30.4 (29.0; 31.8)   1.7 (--0.6; 3.9)       .345     .866
   12 wk            3                25.6 (17.0; 34.2)   --1.2 (--14.8; 12.4)           1.000   149   32.6 (31.0; 34.1)   3.8 (1.4; 6.3)         \<.001   .757
   26 wk                                                                                        124   34.6 (32.9; 36.4)   5.9 (2.9; 8.9)         \<.001   
  SF-36v2 MCS                                                                                                                                             
   Baseline         32               40.8 (36.6; 45.1)                                          199   44.0 (42.0; 45.9)                                   .875
   6 wk             12               39.4 (33.1; 45.7)   --1.5 (--11.3; 8.4)            1.000   156   46.2 (44.2; 48.2)   2.3 (--0.6; 5.1)       .239     .453
   12 wk            3                39.6 (29.2; 50.0)   --1.2 (--17.7; 15.2)           1.000   149   48.0 (46.1; 49.9)   4.0 (1.0; 7.0)         .001     .761
   26 wk                                                                                        124   48.3 (46.2; 50.5)   4.4 (1.0; 7.8)         .003     
  SOSGOQ2.0 Total                                                                                                                                         
   Baseline         30               46.3 (40.2; 52.4)                                          197   50.8 (48.1; 53.4)                                   .870
   6 wk             14               48.1 (39.1; 57.1)   1.8 (--13.3; 16.9)             1.000   158   61.4 (58.5; 64.4)   10.7 (6.1; 15.3)       \<.001   .101
   12 wk            3                48.7 (31.8; 65.5)   2.4 (--24.5; 29.2)             1.000   149   66.2 (63.3; 69.1)   15.4 (10.7; 20.1)      \<.001   .465
   26 wk                                                                                        125   68.9 (65.9; 71.8)   18.1 (13.4; 22.8)      \<.001   

There was no difference in patient satisfaction at 6 wk post-treatment (*P* = .484). In both groups, more than 3 quarters of patients were very satisfied or somewhat satisfied with regard to their spinal metastasis treatment. In the SSG, 76.9% were satisfied with their spine tumor management compared to 78.8% in the LSG. No patients were dissatisfied in the SSG compared to 8.1% in the LSG.

A summary of AEs is shown in Table [4](#tbl4){ref-type="table"}. There was no difference in the occurrence of intraoperative AE between both groups (10% vs 11.3%; *P* = 1.000), but there was more postoperative AEs in the SSG (55% vs 35.2%; *P* = .018), and the occurrence of any AEs was also more common in the SSG (57.5% vs 39.0%; *P* = .029). The occurrence of AEs was moreover associated with shorter survival (*P* = .005). However, the extent of the surgery, as measured by blood loss and operative time, did not impact survival in this study.

###### 

Adverse Event Analysis by Survival Group

  Characteristic                            Short survival N = 40   Long survival N = 213   Total N = 253   *P* value
  ----------------------------------------- ----------------------- ----------------------- --------------- -----------
  Any intraoperative adverse event? n (%)                                                                   1.000
   No                                       36 (90.0)               189 (88.7)              225 (88.9)      
   Yes                                      4 (10.0)                24 (11.3)               28 (11.1)       
  Any postoperative adverse event? n (%)                                                                    .018
   No                                       18 (45.0)               138 (64.8)              156 (61.7)      
   Yes                                      22 (55.0)               75 (35.2)               97 (38.3)       
  Any adverse event? n (%)                                                                                  .029
   No                                       17 (42.5)               130 (61.0)              147 (58.1)      
   Yes                                      23 (57.5)               83 (39.0)               106 (41.9)      

DISCUSSION {#sec4}
==========

In this study, we found that improvement in pain and HRQOL at 6 wk postsurgery was more significant in patients who survived more than 3 mo. However, patients with short survival were significantly worse at baseline, as shown by a significantly worse performance status, higher pain level, and lower quality of life making the 2 groups very challenging to compare. When controlling for baseline performance status, we found that HRQOL at 6 wk post-treatment was similar irrespective of patient survival, refuting the dogma that patients with short life expectancy do not benefit from surgical intervention when HRQOL is the desired outcome. This is the first study to challenge the concept that a patient with short survival should not be considered for surgical intervention. Other factors such as baseline performance status, extent of surgical intervention, and of course patient preferences may be more important than an arbitrary 3-mo cutoff.

Patients in both groups had equal satisfaction with their treatment. Shared decision-making and expectations resonated loudly in this patient population. The fact that in their last months of life, 75% of patients were satisfied with their treatment is clinically relevant. However, although satisfaction was assessed specifically for the spinal tumor management, it is possible that this high satisfaction rate may partly be the result of intense medical attention received by patients in their last weeks of life instead of being purely the result of a surgical procedure. The proportion of patients suffering from postoperative AEs seemed to be higher in the SSG. This binominal analysis is, however, difficult to interpret because of the small number of patients and total AEs in the SSG.

With the ongoing advancements of targeted molecular therapy and oncology care in general, it is more difficult to accurately predict the life expectancy of a cancer patient.^[@bib13]^ In the current era of metastatic disease, there are no longer broad categories of histology; for example, lung cancers are not all the same and should not be considered as such.^[@bib14]^ The 2 most well-known prognostic scoring systems for patients with metastatic spine disease (Tokuhashi and Tomita scores) do not incorporate molecular signatures into their scoring systems and do not reflect modern treatments.^[@bib15],[@bib16]^ Many different authors have questioned the current validity of these scoring systems^[@bib10],[@bib17]^ and reported moderate to low overall precision between 33% and 64%.^[@bib4]^ In a recent international MESCC cohort in which the inclusion criteria included a life expectancy above 3 mo, the 3-mo mortality rate was 28%, reiterating once again challenges pertinent to selecting patients based on expected survival.^[@bib9]^ Nevertheless, even including these short-term survivors, the authors reported on a significant improvement of HRQOL at each time point.

To the best of our knowledge, only one other study looked at HRQOL based on survival.^[@bib20]^ They found HRQOL improvement only in patients who lived longer than 6 mo after surgery. The discrepancy with our results may be due to patient selection. They included only patients presenting with acute symptoms of spinal cord compression, whereas only 56% of our surgical cohort had high-grade epidural disease. Their preoperative mean EQ5D score was 0.28, significantly worse than our population (0.47). Moreover, their cohort had an overall median survival of only 108 d, and 34% of our cohort was still alive at 1 yr, pointing to marked differences between the 2 cohorts. Also, we used a disease-specific HRQOL questionnaire proven to be the most efficient to measure quality of life in this patient population,^[@bib21]^ as opposed to a generic outcome tool. In another study looking at patient selection for surgery, Verlaan et al^[@bib22]^ found that poor performance status at presentation was the strongest indicator of poor short-term survival, but quality-of-life changes in this SSG were not assessed.

Costs {#sec4-1}
-----

The importance of costs in oncology care is a rising concern, especially with the scarcity of resources.^[@bib23]^ Oncological spine surgeries can be prohibitively expensive, especially in emerging countries, and as such, there is an urgent need for cost-effectiveness analyses of these interventions. The multitude of recently published economic analyses supports the importance of the matter. A systematic review assessing the cost-effectiveness of surgery in the management of metastatic epidural spinal cord compression concluded that surgery was more effective, but costlier, and that properly conducted cost-effectiveness analyses were lacking.^[@bib3]^ Costs in spinal oncology are correlated to surgical invasiveness.^[@bib24]^ As such, less-invasive options have the potential to be more cost-effective, especially considering patients with short life expectancy. Comparing the high costs of hospitalization vs community care, any intervention with the potential to decrease inpatient care has cost-effectiveness impact. Community care cost savings have the potential to completely offset surgical costs in this patient population.^[@bib25]^ Consequently, we can anticipate significant cost-effectiveness impact of a limited intervention that has the potential to allow a patient to be discharged home sooner. As the cost of an extra day of ambulation has been shown to be \$60, it is easy to foresee cost-effectiveness even in the short survival arm.^[@bib2]^ Better quality studies from a societal perspective using patient-level data are much required to fill this knowledge gap.

The other issue with high spending in spinal oncology care is the opportunity cost. Every dollar spent in a patient with cancer is not spent on another patient with a longer life expectancy. This difficult and delicate ethical question should arise for cancer care, and ultimately jurisdictions and payers will need to make crucial decisions. Optimum cancer care, especially with expensive systemic treatment, immunotherapies, and complex surgeries, might be an unaffordable goal.^[@bib26]^

Strengths and Limitations {#sec4-2}
-------------------------

There are many limitations to our analyses. First, the small number of patients with less than 3 mo survival limited the ability to detect statistically significant predictors and have the power to show intragroup significance and limited the adjustment parameter to 1 (ECOG). This may explain no statistically significant improvement in HRQOL in the short survival group, although the magnitude of improvement was clinically significant and nearly similar in both groups for the EQ-5D. It may also have been underpowered to reveal a statistically significant difference in the SOSGOQ at 6 wk, despite a clinically significant difference. This also renders the interpretation and analysis of the AE data difficult. Second, 24 patients were excluded from the analysis because they were lost to follow-up within 3 mo for reasons other than death. This might have underestimated the patients in the SSG. Third, life expectancy was not collected in the database. It was assumed that surgically treated patients included in this study had a life expectancy of more than 3 mo as per historical inclusion criteria. Fourth, surgery on its own, by delaying systemic treatment, might negatively impact survival in selected cases. This was not determined in this study. Fifth, to answer this study question, only surgical patients were included, which introduces selection bias. No conclusion can be made from this analysis for patients treated with radiation therapy alone. Lastly, performance status at presentation may be hard to interpret. Patients with poor ECOG at presentation secondary to acute cord compression or instability might differ from patient with long-standing poor performance status. To better define how the ECOG evolves preoperatively would be beneficial and will be the subject of further studies.

The results of this study are not to be misinterpreted as an endorsement to operate on every patient with less than 3 mo of expected survival; however, they do give credence to not denying patients surgery based on expected survival alone. Moreover, if we adhere to expected survival criteria, the underestimation of life expectancy and subsequent inadequate treatment of spinal metastasis may deprive patients of deserving treatment. We confirmed that patients with good baseline performance status do benefit and are satisfied from surgical treatment irrespective of survival, and thus should not be turned down for a lack of expected benefit. Also, availability of more limited interventions, such as separation surgery, cement augmentation, minimally invasive instrumentation, and spinal laser interstitial thermal therapy, has substantially changed the morbidity of what can be offered to these patients. Such less-invasive and potentially less-costly options should be considered for patients with short life expectancy.

CONCLUSION {#sec5}
==========

Patients with good baseline performance status may benefit from surgical treatment, even if they survive less than 3 mo. However, the surgical approach should be tailored to consider the patient\'s medical status and expected survival. When adjusted for baseline performance status, HRQOL 6 wk post-treatment is independent of survival. The extent of surgical intervention, baseline performance status, and patient preferences should be at the forefront of the decision-making process. Even if we could accurately predict survival, life expectancy on its own should not be an exclusion criterion for surgical intervention.
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